Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Hair loss discussion includes Minoxidil, finasteride, and RU58841 treatments. Hope Medicine has a new CEO, possibly leading to HMI's termination.

A user discusses mild/moderate hair loss and considers switching from oral to topical finasteride due to past endocrine issues. They seek feedback on topical finasteride's effectiveness and reputable sources, with replies suggesting Minoxidilmax products as effective alternatives.

Concerns about the integrity of Dr. Melissa Toyos' marketing for Verteporfin treatment, suggesting photos may be digitally altered. Users express skepticism about the treatment's promotion and results.

Concerns about the legitimacy and transparency of a hair clinic's advertising and credentials. Seeking advice on how to research and verify clinics and surgeons effectively.

A college student is embarrassed after their roommate found and mocked their hair loss medications, including Minoxidil and finasteride. The student is advised to report the privacy violation and consider finding a new roommate.

Hair loss discussion involving finasteride's side effects and effectiveness. Users shared mixed experiences, with some reporting side effects and others seeing positive results.

HopeMed is upset with Absci for allegedly using misleading information about HMI-115's performance compared to ABS-201. HopeMed plans to take legal action to protect its confidential data and trade secrets.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

A user was embarrassed by a pharmacist's loud mention of "minoxidil" for hair loss, sparking a discussion on the stigma and unprofessionalism. Users suggested online purchases or different pharmacies for privacy and reassured that most people don't notice others' purchases.

The conversation discusses the emotional impact of hair loss and the importance of taking personal responsibility for treatment decisions. The original poster ignored others' opinions and started using finasteride, expressing relief and frustration over external influences delaying treatment.

Finasteride prescriptions in France now require an annual certificate acknowledging psychiatric and sexual risks, as the European Medicines Agency recognizes these risks. The conversation discusses the potential mental health effects of Finasteride, with some users reporting side effects and others questioning the statistical significance of these findings.

A young man is mocked online for discussing his hair loss and using treatments like Minoxidil and finasteride. Many criticize him for his appearance and choice to use medication, while others defend his right to seek treatment and express frustration over societal double standards.

Concerns about the reliability of KX-826's phase 3 results from China due to potential fraud in clinical trials. Discussion includes skepticism about trusting these results.

Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

Finasteride can cause persistent side effects, including mental health issues, and it's important to consult a doctor before starting. Baseline tests for testosterone, DHT, estradiol, and semen analysis are recommended, and caution is advised for those with a history of depression, anxiety, or diabetes.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

A 19-year-old is frustrated with doctors giving misleading information about hair loss treatments, specifically finasteride and minoxidil. They plan to self-administer finasteride due to concerns about side effects and lack of supportive medical guidance.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Finasteride users discuss potential side effects, including Post Finasteride Syndrome (PFS), with varying opinions on its legitimacy and impact. Some users report side effects like changes in semen consistency and reduced pre-ejaculate, while others emphasize the rarity and reversibility of side effects.

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

Dutasteride in semen is considered a very small risk for partners, and fertility typically improves after stopping the medication. It is recommended to stop Dutasteride 3-6 months before trying to conceive to avoid potential impacts on fertility and fetal development.

Red flags to watch for when choosing a hair transplant clinic, such as high-pressure sales tactics, unclear surgeon assignments, and unrealistic promises. A user shared a positive experience with Skin Medics UK, highlighting transparency and personalized care.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.